- Report
- May 2018
- 204 Pages
Global
From €2088EUR$2,349USD£1,822GBP
- Report
- November 2024
- 100 Pages
Global
From €5288EUR$5,950USD£4,615GBP
- Report
- March 2022
- 300 Pages
Global
From €3555EUR$4,000USD£3,102GBP
- Report
- March 2024
- 30 Pages
Global
From €1955EUR$2,200USD£1,706GBP
€2444EUR$2,750USD£2,133GBP
- Report
- October 2024
- 318 Pages
Global
From €5653EUR$6,360USD£4,933GBP
€7066EUR$7,950USD£6,166GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €1955EUR$2,200USD£1,706GBP
€2444EUR$2,750USD£2,133GBP
- Report
- March 2024
- 30 Pages
Global
From €1955EUR$2,200USD£1,706GBP
€2444EUR$2,750USD£2,133GBP
- Report
- March 2024
- 30 Pages
Global
From €1955EUR$2,200USD£1,706GBP
€2444EUR$2,750USD£2,133GBP
- Report
- March 2024
- 30 Pages
Global
From €1955EUR$2,200USD£1,706GBP
€2444EUR$2,750USD£2,133GBP
- Report
- March 2024
- 30 Pages
Global
From €1955EUR$2,200USD£1,706GBP
€2444EUR$2,750USD£2,133GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP
- Report
- March 2024
- 30 Pages
Global
From €2311EUR$2,600USD£2,017GBP
€2888EUR$3,250USD£2,521GBP

The Parkinson Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Parkinson's Disease is a progressive neurological disorder that affects movement, and is caused by a lack of dopamine in the brain. Parkinson Drugs are used to treat the symptoms of the disease, and can include levodopa, dopamine agonists, monoamine oxidase inhibitors, and catechol-O-methyltransferase inhibitors. These drugs can help to improve motor function, reduce tremors, and improve quality of life.
The Parkinson Drug market is highly competitive, with many companies offering a range of treatments. Some of the major players in the market include AbbVie, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more